Store documents, images and music permanently on CDs. Pro quality at an economical price. Great for video, audio, artwork and sales presentations. 700MB/80 minute record time.
Free Shipping Available. Buy on eBay. Money Back Guarantee!
Search results
- The New York-based private equity firm signed a lease spanning six floors and roughly 144,000 square feet (13,400 square meters), at the 41-story office tower in Midtown Manhattan, landlord Olayan Group said in a statement Tuesday. CD&R is more than doubling its New York footprint with the new lease.
news.bloomberglaw.com/private-equity/cd-r-relocates-headquarters-to-renovated-manhattan-skyscraperCD&R Relocates Headquarters to Renovated Manhattan Skyscraper
Jun 20, 2023 · Private Equity Firm CD&R Relocates Headquarters to Renovated Manhattan Skyscraper. Finance firm will sign lease for space at 550 Madison Ave. Olayan Group has been revamping the New York office...
Jun 20, 2023 · Private equity firm Clayton Dubilier & Rice (CD&R) will more than double its New York City headquarters in a move to 144,000 square feet at 550 Madison Avenue. CD&R inked a more than 10-year lease to relocate from 70,000 square feet at the Seagram Building.
- Celia Young
270 Park Avenue, also known as the JPMorgan Chase Building, is a supertall skyscraper under construction on the East Side of the Midtown neighborhood of Manhattan in New York City. Designed by the firm of Foster + Partners, the skyscraper is expected to rise 1,388 feet (423 m) when completed in 2025. Photograph of immediate past building.
Private equity firm Clayton Dubilier & Rice is relocating its headquarters to in New York to a newly renovated skyscraper on Madison Avenue.
Headquarters. Seagram Building. New York City, New York, U.S. AUM. US$57 billion (2023) Website. www.cdr-inc.com. Clayton, Dubilier & Rice, LLC (CD&R) [1] is an American private equity company. It is one of the oldest private equity investment firms in the world.
5 days ago · CD&R’s offer values the business, which makes over-the-counter pain management and allergy medications, such as Doliprane and Allegra, at €15.5bn. Sanofi would keep a stake of about 50 per ...
